AbbVie Inc. Press Releases

ABBV 
$70.77
*  
0.46
0.65%
Get ABBV Alerts
*Delayed - data as of Jul. 29, 2015  -  Find a broker to begin trading ABBV now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



TECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA Approval as the First and Only All-Oral, Interferon-Free Treatment for Genotype 4 Chronic Hepatitis C in the U.S.
7/24/2015 2:00:00 PM - PR Newswire
▲4.03 % Price Change since this news event. The Volume Ratio is 2.55.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Reports Second-Quarter 2015 Financial Results
7/24/2015 7:53:00 AM - PR Newswire
▼-1.02 % Price Change since this news event. The Volume Ratio is 2.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


C2N and AbbVie Announce FDA Orphan Drug Designation of C2N-8E12 (ABBV-8E12) for the Treatment of Progressive Supranuclear Palsy
7/17/2015 8:01:00 AM - PR Newswire
▲1.11 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


IMBRUVICA® (ibrutinib) Now Approved to Treat Waldenstrom''s Macroglobulinemia in Europe
7/10/2015 7:10:00 AM - PR Newswire
▲4.41 % Price Change since this news event. The Volume Ratio is 1.2.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
6/24/2015 6:00:00 AM - PR Newswire
▲0.74 % Price Change since this news event. The Volume Ratio is 1.18.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Declares Quarterly Dividend
6/18/2015 5:01:00 PM - PR Newswire
▲2.59 % Price Change since this news event. The Volume Ratio is 1.38.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders
6/12/2015 9:00:00 AM - PR Newswire
▲4.01 % Price Change since this news event. The Volume Ratio is 1.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
6/12/2015 2:30:00 AM - PR Newswire
▲4.01 % Price Change since this news event. The Volume Ratio is 0.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally
6/8/2015 8:00:00 AM - PR Newswire
▲4.23 % Price Change since this news event. The Volume Ratio is 1.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress
6/8/2015 8:00:00 AM - PR Newswire
▲4.23 % Price Change since this news event. The Volume Ratio is 1.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference
6/5/2015 4:00:00 PM - PR Newswire
▲5.00 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ibrutinib (IMBRUVICA®) Improved Survival for Treatment-Naive Chronic Lymphocytic Leukemia Patients in Phase III RESONATE™-2 Trial
6/4/2015 9:20:00 AM - PR Newswire
▲5.61 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015
6/4/2015 7:00:00 AM - PR Newswire
▲5.61 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






AbbVie to Present at Jefferies 2015 Healthcare Conference
6/1/2015 12:22:00 PM - PR Newswire
▲5.52 % Price Change since this news event. The Volume Ratio is 0.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting
6/1/2015 8:00:00 AM - PR Newswire
▲5.94 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Analysis of Phase III RESONATE™ Data Shows Adherence to the Recommended 420mg Dose of IMBRUVICA® (ibrutinib) Results in Improved Efficacy Benefits in Patients with Chronic Lymphocytic Leukemia
5/31/2015 9:01:00 AM - PR Newswire
▲5.94 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
5/31/2015 8:00:00 AM - PR Newswire
▲5.94 % Price Change since this news event. The Volume Ratio is 0.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day